Therefore, any transcriptional, translational, or migratory changes seen in the Ewing sarcoma cells treated with exogenous recombinant Wnt5a result from activation of a beta-catenin-independent Wnt signaling pathway. The gene discussed is WNT5A; the disease is Ewing sarcoma.